1-3 of 3
Justin Shang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Claire Roddie, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin A Pule, Justin Shang, Elias Jabbour
Journal: Blood
Blood (2024) 144 (Supplement 1): 4845.
https://doi.org/10.1182/blood-2024-208028
Published: 2024
Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Jae H. Park, Elias Jabbour, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Justin Shang, Claire Roddie
Journal: Blood
Blood (2024) 144 (Supplement 1): 3458.
https://doi.org/10.1182/blood-2024-201514
Published: 2024
Journal Articles

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Kate Cwynarski, Gloria Iacoboni, Eleni Tholouli, Tobias F. Menne, David A. Irvine, Nivetha Balasubramaniam, Leigh Wood, Justin Shang, Yiyun Zhang, Silvia Basilico, Birgit Huber, Mary Vinson, Koki Lilova, Wolfram Brugger, Martin Pule
Journal: Blood
Blood (2022) 140 (Supplement 1): 10316–10317.
https://doi.org/10.1182/blood-2022-165971
Published: 2022